At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 570 enrolled
Drug / intervention
DWP-450 (Botulinum purified neurotoxin, Type A)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Open Label, Single Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines
In Brief
A Phase 2 clinical trial evaluating DWP-450 (Botulinum purified neurotoxin, Type A) for Glabellar Frown Lines. Completed, enrolled 570 participants across 1 site.
Detailed Summary
The primary objective is to demonstrate the safety of multiple doses of DWP-450 purified Botulinum neurotoxin, Type A, in treatment of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlabellar Frown Lines
CountriesUnited States
CollaboratorsPPD Development, LP
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartMay 2015
Primary CompletionOct 2016
Study CompletionNov 2016
TodayJul 2026
First PostedApr 29, 2015
Enrollment StartMay 1, 2015
Primary CompletionOct 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.2 years ago
Interventions
DWP-450 (Botulinum purified neurotoxin, Type A)biological
Botulinum toxin, Type A